Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period.

Autor: Fomina DS; Department of Allergy and Immunology, City Clinical Hospital No.52 of Moscow Healthcare Department, Moscow, Russia.; Allergy and Immunology Department, Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia., Lebedkina MS; Department of Allergy and Immunology, City Clinical Hospital No.52 of Moscow Healthcare Department, Moscow, Russia., Iliukhina AA; State Virus Collection Laboratory, Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Kovyrshina AV; State Virus Collection Laboratory, Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Shelkov AY; State Virus Collection Laboratory, Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Andreev SS; Department of Allergy and Immunology, City Clinical Hospital No.52 of Moscow Healthcare Department, Moscow, Russia., Chernov AA; Department of Allergy and Immunology, City Clinical Hospital No.52 of Moscow Healthcare Department, Moscow, Russia., Dolzhikova IV; State Virus Collection Laboratory, Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Kruglova TS; Department of Allergy and Immunology, City Clinical Hospital No.52 of Moscow Healthcare Department, Moscow, Russia., Andrenova GV; Department of Allergy and Immunology, City Clinical Hospital No.52 of Moscow Healthcare Department, Moscow, Russia., Tukhvatulin AI; State Virus Collection Laboratory, Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Shcheblyakov DV; State Virus Collection Laboratory, Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Karaulov AV; Allergy and Immunology Department, Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia., Lysenko MA; Department of Allergy and Immunology, City Clinical Hospital No.52 of Moscow Healthcare Department, Moscow, Russia.; General Therapy Department, Pirogov Russian National Research Medical University, Moscow, Russia., Logunov DY; State Virus Collection Laboratory, Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Gintsburg AL; State Virus Collection Laboratory, Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia.; Allergy and Immunology Department, Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia.

Publikováno v: Frontiers in immunology [Front Immunol] 2023 Oct 20; Vol. 14, pp. 1259725. Date of Electronic Publication: 2023 Oct 20 (Print Publication: 2023).

[Pre-exposure prophylaxis of new COVID-19 coronavirus infection with tixagevimab/cilgavimab in adult Moscow patients with primary immunodeficiencies].

Autor: Roppelt AA; City Clinical Hospital №52.; Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology., Lebedkina MS; City Clinical Hospital №52., Chernov AA; City Clinical Hospital №52.; Russian Medical Academy of Continuous Professional Education., Kruglova TS; City Clinical Hospital №52., Mukhina OA; City Clinical Hospital №52., Yukhnovskaya YD; Sechenov First Moscow State Medical University (Sechenov University)., Samedova FA; Sechenov First Moscow State Medical University (Sechenov University)., Mаrkina UA; City Clinical Hospital №52., Andrenova GV; City Clinical Hospital №52., Karaulov AV; Sechenov First Moscow State Medical University (Sechenov University)., Lysenko MA; City Clinical Hospital №52.; Pirogov Russian National Research Medical University., Fomina DS; City Clinical Hospital №52.; Sechenov First Moscow State Medical University (Sechenov University).

Publikováno v: Terapevticheskii arkhiv [Ter Arkh] 2023 Feb 24; Vol. 95 (1), pp. 78-84. Date of Electronic Publication: 2023 Feb 24.

Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study.

Autor: Bryushkova EA; Pirogov Russian National Research Medical University, Moscow, Russia.; Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, Russia.; Lomonosov Moscow State University, Moscow, Russia., Skatova VD; Pirogov Russian National Research Medical University, Moscow, Russia.; Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, Russia., Mutovina ZY; City Clinical Hospital No.52 of Moscow Healthcare Department, Moscow, Russia., Zagrebneva AI; City Clinical Hospital No.52 of Moscow Healthcare Department, Moscow, Russia., Fomina DS; City Clinical Hospital No.52 of Moscow Healthcare Department, Moscow, Russia.; I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russian Federation., Kruglova TS; City Clinical Hospital No.52 of Moscow Healthcare Department, Moscow, Russia., Akopyan AA; Pirogov Russian National Research Medical University, Moscow, Russia., Strazhesko ID; Pirogov Russian National Research Medical University, Moscow, Russia., Lukyanov SA; Pirogov Russian National Research Medical University, Moscow, Russia., Tkacheva ON; Pirogov Russian National Research Medical University, Moscow, Russia., Lysenko MA; Pirogov Russian National Research Medical University, Moscow, Russia.; City Clinical Hospital No.52 of Moscow Healthcare Department, Moscow, Russia., Chudakov DM; Pirogov Russian National Research Medical University, Moscow, Russia.; Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, Russia.

Publikováno v: PloS one [PLoS One] 2022 Aug 24; Vol. 17 (8), pp. e0273340. Date of Electronic Publication: 2022 Aug 24 (Print Publication: 2022).

[Efficacy and safety of regdanvimab in patients with mild/moderate COVID-19 and high risk of progression of the disease: a retrospective study in a short-term stay unit].

Autor: Markina UA; City Clinical Hospital №52., Fomina DS; Sechenov First Moscow State Medical University (Sechenov University).; Moscow City Scientific and Practical Center of Allergology and Immunology of City Clinical Hospital №52., Lebedkina MS; City Clinical Hospital №52.; Sechenov First Moscow State Medical University (Sechenov University)., Kruglova TS; City Clinical Hospital №52., Chernov AA; City Clinical Hospital №52.; Russian Medical Academy of Continuous Professional Education., Zagrebneva AI; City Clinical Hospital №52.; Pirogov Russian National Research Medical University., Mutovina ZY; City Clinical Hospital №52.; Central State Medical Academy of the President of the Russian Federation., Karaulov AV; Sechenov First Moscow State Medical University (Sechenov University)., Alexeeva EI; Sechenov First Moscow State Medical University (Sechenov University).; National Medical Research Center for Children's Health., Lysenko MA; City Clinical Hospital №52.; Pirogov Russian National Research Medical University.

Publikováno v: Terapevticheskii arkhiv [Ter Arkh] 2022 Jun 17; Vol. 94 (5), pp. 675-682. Date of Electronic Publication: 2022 Jun 17.

Temporal Clinical and Laboratory Response to Interleukin-6 Receptor Blockade With Tocilizumab in 89 Hospitalized Patients With COVID-19 Pneumonia.

Autor: Fomina DS; City Clinical Hospital No.52 of Moscow Healthcare Department, Moscow, Russia.; First Sechenov Moscow State Medical University of the Ministry of Healthcare of the Russian Federation, Moscow, Russia., Lysenko MA; City Clinical Hospital No.52 of Moscow Healthcare Department, Moscow, Russia.; Pirogov Russian National Research Medical University (RNRMU) of the Ministry of Healthcare, Moscow, Russia., Beloglazova IP; City Clinical Hospital No.52 of Moscow Healthcare Department, Moscow, Russia.; Pirogov Russian National Research Medical University (RNRMU) of the Ministry of Healthcare, Moscow, Russia., Mutovina ZY; City Clinical Hospital No.52 of Moscow Healthcare Department, Moscow, Russia.; Federal State Institution of Additional Professional Education 'Central State Medical Academy' of the President of the Russian Federation, Moscow, Russia., Poteshkina NG; City Clinical Hospital No.52 of Moscow Healthcare Department, Moscow, Russia.; Pirogov Russian National Research Medical University (RNRMU) of the Ministry of Healthcare, Moscow, Russia., Samsonova IV; City Clinical Hospital No.52 of Moscow Healthcare Department, Moscow, Russia., Kruglova TS; City Clinical Hospital No.52 of Moscow Healthcare Department, Moscow, Russia., Chernov AA; City Clinical Hospital No.52 of Moscow Healthcare Department, Moscow, Russia.; Russian Medical Academy of Continuing Professional Education, Moscow, Russia., Karaulov AV; First Sechenov Moscow State Medical University of the Ministry of Healthcare of the Russian Federation, Moscow, Russia.

Publikováno v: Pathogens & immunity [Pathog Immun] 2020 Oct 02; Vol. 5 (1), pp. 327-341. Date of Electronic Publication: 2020 Oct 02 (Print Publication: 2020).